OBJECTIVE: The persistence of myeloid-derived cells in the artery wall is a characteristic of advanced atherosclerotic plaques. However, the mechanisms by which these cells are retained are poorly understood. Semaphorins, a class of neuronal guidance molecules, play a critical role in vascular patterning and development, and recent studies suggest that they may also have immunomodulatory functions. The present study evaluates the expression of Semaphorin 3E (Sema3E) in settings relevant to atherosclerosis and its contribution to macrophage accumulation in plaques. APPROACH AND RESULTS: Immunofluorescence staining of Sema3E, and its receptor PlexinD1, demonstrated their expression in macrophages of advanced atherosclerotic lesions of Apoe(-/-) mice. Notably, in 2 different mouse models of atherosclerosis regression, Sema3E mRNA was highly downregulated in plaque macrophages, coincident with a reduction in plaque macrophage content and an enrichment in markers of reparative M2 macrophages. In vitro, Sema3E mRNA was highly expressed in inflammatory M1 macrophages and in macrophages treated with physiological drivers of plaque progression and inflammation, such as oxidized low-density lipoprotein and hypoxia. To explore mechanistically how Sema3E affects macrophage behavior, we treated macrophages with recombinant protein in the presence/absence of chemokines, including CCL19, a chemokine implicated in the egress of macrophages from atherosclerotic plaques. Sema3E blocked actin polymerization and macrophage migration stimulated by the chemokines, suggesting that it may immobilize these cells in the plaque. CONCLUSIONS: Sema3E is upregulated in macrophages of advanced plaques, is dynamically regulated by multiple atherosclerosis-relevant factors, and acts as a negative regulator of macrophage migration, which may promote macrophage retention and chronic inflammation in vivo.
OBJECTIVE: The persistence of myeloid-derived cells in the artery wall is a characteristic of advanced atherosclerotic plaques. However, the mechanisms by which these cells are retained are poorly understood. Semaphorins, a class of neuronal guidance molecules, play a critical role in vascular patterning and development, and recent studies suggest that they may also have immunomodulatory functions. The present study evaluates the expression of Semaphorin 3E (Sema3E) in settings relevant to atherosclerosis and its contribution to macrophage accumulation in plaques. APPROACH AND RESULTS: Immunofluorescence staining of Sema3E, and its receptor PlexinD1, demonstrated their expression in macrophages of advanced atherosclerotic lesions of Apoe(-/-) mice. Notably, in 2 different mouse models of atherosclerosis regression, Sema3E mRNA was highly downregulated in plaque macrophages, coincident with a reduction in plaque macrophage content and an enrichment in markers of reparative M2 macrophages. In vitro, Sema3E mRNA was highly expressed in inflammatory M1 macrophages and in macrophages treated with physiological drivers of plaque progression and inflammation, such as oxidized low-density lipoprotein and hypoxia. To explore mechanistically how Sema3E affects macrophage behavior, we treated macrophages with recombinant protein in the presence/absence of chemokines, including CCL19, a chemokine implicated in the egress of macrophages from atherosclerotic plaques. Sema3E blocked actin polymerization and macrophage migration stimulated by the chemokines, suggesting that it may immobilize these cells in the plaque. CONCLUSIONS:Sema3E is upregulated in macrophages of advanced plaques, is dynamically regulated by multiple atherosclerosis-relevant factors, and acts as a negative regulator of macrophage migration, which may promote macrophage retention and chronic inflammation in vivo.
Authors: M Janabi; S Yamashita; K Hirano; N Sakai; H Hiraoka; K Matsumoto; Z Zhang; S Nozaki; Y Matsuzawa Journal: Arterioscler Thromb Vasc Biol Date: 2000-08 Impact factor: 8.311
Authors: Eugene Trogan; Robin P Choudhury; Hayes M Dansky; James X Rong; Jan L Breslow; Edward A Fisher Journal: Proc Natl Acad Sci U S A Date: 2002-02-12 Impact factor: 11.205
Authors: Luitpold E Miller; Claudia Weidler; Werner Falk; Peter Angele; Jens Schaumburger; Jürgen Schölmerich; Rainer H Straub Journal: Arthritis Rheum Date: 2004-04
Authors: Igor Chereshnev; Eugene Trogan; Sabina Omerhodzic; Vitalii Itskovich; Juan-Gilberto Aguinaldo; Zahi A Fayad; Edward A Fisher; Ernane D Reis Journal: J Surg Res Date: 2003-05-15 Impact factor: 2.192
Authors: Jonathan E Feig; Yuliya Vengrenyuk; Vladimir Reiser; Chaowei Wu; Alexander Statnikov; Constantin F Aliferis; Michael J Garabedian; Edward A Fisher; Oscar Puig Journal: PLoS One Date: 2012-06-27 Impact factor: 3.240
Authors: N Sato; S K Ahuja; M Quinones; V Kostecki; R L Reddick; P C Melby; W A Kuziel; S S Ahuja Journal: J Exp Med Date: 2000-07-17 Impact factor: 14.307
Authors: Kathryn J Moore; Simon Koplev; Edward A Fisher; Ira Tabas; Johan L M Björkegren; Amanda C Doran; Jason C Kovacic Journal: J Am Coll Cardiol Date: 2018-10-30 Impact factor: 24.094